Last reviewed · How we verify

Next Gen Pharma India Pvt. Ltd. — Portfolio Competitive Intelligence Brief

Next Gen Pharma India Pvt. Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lactobacillus brevis CD2 Lozenges Lactobacillus brevis CD2 Lozenges phase 3 Live biotherapeutic product (probiotic) Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Massachusetts General Hospital · 1 shared drug class
  2. University of Hohenheim · 1 shared drug class
  3. University of Sao Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Next Gen Pharma India Pvt. Ltd.:

Cite this brief

Drug Landscape (2026). Next Gen Pharma India Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/next-gen-pharma-india-pvt-ltd. Accessed 2026-05-16.

Related